Molina MW, Sibaja ML

Language: Spanish
References: 15
Page: 47-52
PDF size: 183.90 Kb.

ABSTRACT

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a new entity, where the highest incidence is in relation to the use of intravenous bisphosphonates. The three most common pathophysiologic mechanisms are postulated: remodeling suppression, abnormal angiogenesis and infection. The aim of this article is to review current recommendations for diagnosis and treatment of this disease so little known and rare, but important impact on patient health.

REFERENCES

1. Allen M. Biphosphonates and Osteonecrosis of the Jaw : Moving from the bedside to the Bench. Cells tissues Organs (2009); 189:289-294.

2. Bocanegra S, Vicente M, Sosa M et al. Osteonecrosis of the Jaw secondary to oral alendronate. Rev Méd Chile. (2009); 137:275-279.

3. Casal C, Someso E, Rey E et al. Osteonecrosis mandibular: Un problema importante poco conocido de la terapia con bifosfonatos. Cad Aten Primaria (2011); 18: 20-23.

4. Drake M, Clarke B and Khosla S. Biphosphonates: Mechanism of Action and Role in Clinical Practice, Mayo Clin Proc (2008); 83 (9):1032-1045.

5. Hansen T, Kunkel M, Weber A, et al. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35:155-160.

6. Jaimes M, Chaves N, Olate S et al. Bifosfonatos asociado a osteonecrosis de los maxilares. Int. J. Morphol. (2008); 26(3):681-688.

7. Jaimes M, Oliviera GR, Olate S et al. Bifosfonatos asociado a osteonecrosis de los maxilares . AVANCES EN ODONTOESTOMATOLOGIA. (2008); 24(3):219-226.

8. Lopes I, Zenha H, Costa H et al. Osteonecrose da Mandíbula Associada ao Uso de Bifosfonatos: Uma Patologia Secundária Grave. ARQUIVOS DE MEDICINA (2009); 23(5):181-185.

9. Marx R, Cillo J and Ulloa J. Oral Bisphosphonate-Induced Osteonecrosis. J Oral Maxillofac Surg. (2007); 65: 2397-2410.

10. Otero J, Rollón A, Coello J, et al. Osteonecrosis de los maxilares asociada al uso de bifosfonatos. REV ESP CIR ORAL MAXILOFAC (2011); 33(1):15-21

11. Ruggiero S, Dodson T, Landesberg R et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws—2009 Update. J Oral Maxillofac Surg (2009); 67 (1): 2-12.

12. Smith S, Recker R, Muller H, et al. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys.Bone: 32: 45-55.

13. Sosa M, Gómez MJ, Bagán J y col. Osteonecrosis de los maxilares: Documento de consenso. Rev Osteoporos Metab Miner (2009); 1(1): 41-51.

14. Wirth Scott, Lawson Amber and Stutphin Stephanie. Osteonecrosis of the Jaw Associated With Bisphosphonate Therapy. ORTHOPEDICS (2009); 32 (12): 900-903.

15. Yamashita J, McCauley L and Van Poznak C. Updates on Osteonecrosis of the Jaw. Curr Opin Support Palliat Care. (2010); 4 (3):200-206.